News

Regeneron Pharmaceuticals and Sanofi have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval…
Read More...

CytoReason announced that it has entered into a collaboration agreement with Pfizer that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive…
Read More...

GE Healthcare and Vanderbilt University Medical Center (VUMC) announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will…
Read More...

AmpliPhi Biosciences Corporation and C3J Therapeutics announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge…
Read More...

Recipharm announces that it will initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK. The decision to…
Read More...

Merck KGaA, Darmstadt, Germany announced that through its wholly owned subsidiary, Ares Trading, it has evolved its agreement with Intrexon Corporation for the development of Chimeric…
Read More...

Eli Lilly and Company and Aduro Biotech, Inc. announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and…
Read More...

Gilead Sciences and Agenus Inc. announced the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel…
Read More...

Novartis announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO)…
Read More...

Novartis announced that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology. She will…
Read More...

TOKYO & Astellas Pharma Inc. and Pfizer Inc. announced that the Phase 3 ARCHES trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, controlled, Phase…
Read More...

Mustang Bio announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MB-102 (CD123 CAR T) for the treatment of blastic plasmacytoid dendritic…
Read More...

WuXi Biologics and AC Immune announced the first steps of an exclusive strategic collaboration that covers biologics discovery, development and manufacturing. AC Immune and WuXi…
Read More...

Ascentage Pharma announced that it has entered into a strategic collaboration with Genor Biopharma Co. Ltd. ("Genor"). As part of the agreement, the companies will explore the synergies…
Read More...

Sandoz, a Novartis division and the pioneer and global leader in biosimilars, announced that it has entered into an agreement to commercialize biosimilar versions of insulins used in…
Read More...

Pfizer Inc. and GlaxoSmithKline plc announced that they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of…
Read More...

Amgen and Molecular Partners AG announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical…
Read More...

Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with Daewoong Pharmaceutical…
Read More...